Skip to content

Inhibrx Biosciences, Inc. INBX Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
Exelixis logo
ExelixisEXEL
Incyte logo
IncyteINCY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX

Other financials

Income statement

See full
Revenue--100%
Operating income-$30.9M+27.9%
Net income-$33.4M+22.8%
EPS (diluted)-$2.15+23.2%

Balance sheet

See full
Cash & equivalents$161.7M-25.3%
Total debt$180.9M+69.8%
Total equity-$21.0M-122%
Total assets$184.0M-24.2%

Cash flow

See full
Operating cash flow-$38.0M-5.9%
CapEx--100%
Free cash flow-$38.0M-5.9%

Valuation

See full
Market cap$1.4B+385%
Enterprise value$1.42B+982%
P/S1,073.7×-280×

Profitability

See full
Operating margin-10,386.5%-5,025pp
Net margin-10,773.5%-878,492pp
FCF margin-9,986.5%-4,727pp

Returns & leverage

See full
Return on equity-197.8%-2,158pp
Debt / equity13.4×+13.3×
Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s preferred stock, shares issued.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s preferred stock, shares issued?
Inhibrx Biosciences, Inc. (INBX) reported preferred stock, shares issued of $0 in Q1 2026.